Aktis Oncology reaches its May 22 earnings date with the short-seller dynamic that had been easing now quietly reversing.
The shift is modest but directionally clear. Short interest has climbed roughly 9% over the past month to around 2.45 million shares — a reversal from the deceleration noted ahead of the May 15 print. The ORTEX short score holds at 70.4, essentially unchanged over the past two weeks, suggesting the market has found a settled level of skepticism rather than moving decisively in either direction. The cost to borrow has eased from a recent peak near 2.7% to around 2.1%, and borrow availability is in the moderate range at roughly 99% — meaning there is ample supply for new short positions should sentiment shift further.
The bull case rests on a shareholder table that remains unusually well-anchored for a clinical-stage name. Eli Lilly holds approximately 11.5% of shares — a strategic position that carries different weight than a typical passive allocation — while specialist healthcare funds including EcoR1, Vida Ventures, and T. Rowe Price collectively account for another 30% or more of the register. Analyst coverage has grown steadily since late 2025, with JP Morgan, Leerink Partners, William Blair, and HC Wainwright all initiating with positive ratings. HC Wainwright lifted its target from $30 to $33 following the March print. The mean target of $32.25 implies roughly 69% upside to the current $19.12 price — a gap that reflects either deep conviction in the pipeline or the market's reluctance to assign value ahead of clinical proof points.
Bears have the price chart on their side. The stock has fallen about 8% over the past month and is down nearly 2% on the week, underperforming a biotech tape that has been broadly constructive. The negative earnings yield and price-to-book near 7.5x are hard to square with fundamental metrics for a pre-revenue oncology company — valuation here is entirely a function of pipeline optionality. Two recent earnings events generated sharp one-day moves of +6% and +18% respectively, which illustrates just how binary clinical-stage catalysts can be for a name of this size and ownership concentration.
The print will test whether Aktis's targeted alpha therapy data can give the market a concrete reason to close the gap between the current price and what a well-credentialled institutional register believes it is worth.
See the live data behind this article on ORTEX.
Open AKTS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
